Literature DB >> 16082514

Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons.

L K Nilsson1, K R Linderholm, S Erhardt.   

Abstract

Acute elevation of the endogenous NMDA-receptor antagonist kynurenic acid (KYNA) is associated with an increased neuronal activity of rat ventral tegmental area (VTA) dopamine (DA) neurons and disruption in prepulse inhibition (PPI). In the present study, the effects of subchronic exposure to kynurenine and probenecid (20 mg/kg/day and 10 mg/kg/day, respectively for 14 days), aiming at increasing brain KYNA turnover, on rat VTA dopaminergic firing and on PPI were investigated. This treatment increased neuronal firing of VTA DA neurons, changed the response of these neurons to systemically administered nicotine (3-400 microg/kg, i.v.) and tended to disrupt PPI. Present results show that the effect on firing of VTA DA neurons by acutely elevated levels of brain KYNA also persists following subchronic exposure. In addition, no adaptive changes seem to occur with regard to the electrophysiological effects of KYNA on VTA DA neurons following subchronic treatment with kynurenine and probenecid.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082514     DOI: 10.1007/s00702-005-0343-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.850


  93 in total

1.  Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain.

Authors:  C Wang; V M Showalter; G R Hillman; K M Johnson
Journal:  J Neurosci Res       Date:  1999-03-15       Impact factor: 4.164

2.  Effect of phencyclidine in chronic schizophrenics.

Authors:  T Itil; A Keskiner; N Kiremitci; J M Holden
Journal:  Can Psychiatr Assoc J       Date:  1967-04

3.  Modulation of extracellular kynurenic acid content by excitatory amino acids in primary cultures of rat astrocytes.

Authors:  L Curatolo; C Caccia; C Speciale; L Raimondi; M Cini; M Marconi; A Molinari; R Schwarcz
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

Review 4.  Quinolinic acid and other kynurenines in the central nervous system.

Authors:  T W Stone; J H Connick
Journal:  Neuroscience       Date:  1985-07       Impact factor: 3.590

5.  Kynurenic acid inhibits the activation of kainic and N-methyl-D-aspartic acid-sensitive ionotropic receptors by a different mechanism.

Authors:  M Bertolino; S Vicini; E Costa
Journal:  Neuropharmacology       Date:  1989-05       Impact factor: 5.250

6.  Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo.

Authors:  H Q Wu; P Guidetti; J H Goodman; M Varasi; G Ceresoli-Borroni; C Speciale; H E Scharfman; R Schwarcz
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

7.  Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons.

Authors:  S Erhardt; H Oberg; J M Mathé; G Engberg
Journal:  Amino Acids       Date:  2001       Impact factor: 3.520

8.  Nicotine-induced excitation of midbrain dopamine neurons in vitro involves ionotropic glutamate receptor activation.

Authors:  P Grillner; T H Svensson
Journal:  Synapse       Date:  2000-10       Impact factor: 2.562

9.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

10.  Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors.

Authors:  D S McGehee; M J Heath; S Gelber; P Devay; L W Role
Journal:  Science       Date:  1995-09-22       Impact factor: 47.728

View more
  22 in total

1.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

Authors:  Kathleen S Alexander; Hui-Qiu Wu; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

2.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

Review 3.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

4.  Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood.

Authors:  Britta Hahn; Carolyn H Reneski; Ana Pocivavsek; Robert Schwarcz
Journal:  Psychopharmacology (Berl)       Date:  2017-11-11       Impact factor: 4.530

5.  Prenatal THC exposure raises kynurenic acid levels in the prefrontal cortex of adult rats.

Authors:  Sarah Beggiato; Alessandro Ieraci; Maria Cristina Tomasini; Robert Schwarcz; Luca Ferraro
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-02-04       Impact factor: 5.067

6.  Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Sara K Olsson; Martin Samuelsson; Peter Saetre; Leif Lindström; Erik G Jönsson; Conny Nordin; Göran Engberg; Sophie Erhardt; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

7.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Authors:  Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

8.  Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice.

Authors:  Sara K Olsson; Markus K Larsson; Sophie Erhardt
Journal:  J Neural Transm (Vienna)       Date:  2011-09-09       Impact factor: 3.575

9.  Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.

Authors:  Maria Holtze; Peter Saetre; Göran Engberg; Lilly Schwieler; Thomas Werge; Ole A Andreassen; Håkan Hall; Lars Terenius; Ingrid Agartz; Erik G Jönsson; Martin Schalling; Sophie Erhardt
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

Review 10.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.